The extracorporeal membrane oxygenation (ECMO) procedure aids in the provision of prolonged cardiopulmonary support, whereas the Impella device (Abiomed, Danvers, MA) is a ventricular assist device that maintains circulation by pumping blood into the aorta from the left ventricle. Blood is circulated in parallel with the heart by Impella. It draws blood straight into the aorta from the left ventricle, hence preserving the physiological flow. ECMO bypasses the left atrium and the left ventricle, and the end consequence is a non-physiological flow. In this article, we conducted a detailed analysis of various publications in the literature and examined various modalities pertaining to the use of ECMO and Impella for cardiogenic shocks, such as efficacy, clinical outcomes, cost-effectiveness, device-related complications, and limitations. The Impella completely unloads the left ventricle, thereby significantly reducing the effort of the heart. Comparatively, ECMO only stabilizes a patient with cardiogenic shock for a short stretch of time and does not lessen the efforts of the left ventricle ("unload" it). In the acute setting, both devices reduced left ventricular end-diastolic pressure and provided adequate hemodynamic support. By comparing patients on Impella to those receiving ECMO, it was found that patients on Impella were associated with better clinical results, quicker recovery, limited complications, and reduced healthcare costs; however, there is a lack of conclusive studies performed demonstrating the reduction in long-term mortality rates. Considering the effectiveness of given modalities and taking into account the various studies described in the literature, Impella has reported better clinical outcomes although more clinical trials are needed for establishing the effectiveness of these interventional approaches in revascularization in cardiogenic shock.

Menopause is a natural phase when periods stop and fertility ends, usually between ages 45 and 55, caused by drops in estrogen and progesterone. Common symptoms include hot flashes, night sweats, sleep problems, mood changes, vaginal dryness, and joint or bone discomfort. Hormonal changes can affect heart health, bone strength, bladder control, skin, hair, weight, and memory, but these changes are manageable. Treatments range from hormone therapy and non-hormonal medicines to vaginal creams and medicines for bone health, all tailored to each woman’s needs. Lifestyle habits, pelvic floor exercises, stress management, healthy diet, social support, and community programs can make daily life more comfortable and improve overall well-being.

Heart disease is the leading cause of death in women yet many do not recognize it as their greatest health risk, which leads to delays in care. Women have unique heart risks related to hormones, menopause, pregnancy, and autoimmune conditions that are often overlooked. Symptoms in women are often different and subtle, such as fatigue, nausea, or jaw pain, which can delay diagnosis. Women are less likely to receive recommended tests and treatments despite benefiting equally from standard therapies. Early prevention through regular exercise, a heart-healthy diet, not smoking, limiting alcohol, managing stress, and maintaining a healthy weight can greatly reduce heart disease risk in women.

Neuromyelitis optica spectrum disorder (NMOSD), previously known as Devic disease or neuromyelitis optica (NMO), represents inflammatory conditions affecting the central nervous system. These disorders are characterized by severe immune-mediated demyelination and axonal damage, with a predilection for targeting optic nerves and the spinal cord. Key clinical features of NMOSD encompass acute episodes of bilateral or rapid sequential optic neuritis and transverse myelitis, typically exhibiting a relapsing course. These attacks endure for several days, and recovery varies, spanning from weeks to months. In this report, we present the case of a 35-year-old individual who initially complained of urinary retention, followed by decreasing vision in the left eye and subsequently in the right eye. These visual symptoms were succeeded by weakness in the right upper and lower limbs.

Post-transplant lymphoproliferative disorder (PTLD) involving the central nervous system (CNS) is a rare but serious life-threatening complication seen in recipients of solid organ transplant. Primary CNS encompasses 5–15% of all types of PTLD diagnoses, and heart transplant recipients represent 3–5% of those reported cases. Diagnosis is often delayed due to the highly variable presentation, with some cases remaining undiagnosed for years. Multidisciplinary collaboration is crucial for early diagnosis and management. A 53-year-old woman patient presented with altered mental status. MRI revealed nodular ventriculitis and bilateral periventricular hyperdense infiltrates. CSF studies demonstrated lymphocytic pleocytosis, elevated protein, and EBV-PCR-positive results. A stereotactic brain needle biopsy confirmed the presence of EBV-positive diffuse large B-cell lymphoma, consistent with primary CNS PTLD, 14 months after her heart transplant. Despite appropriate management, the patient experienced progressive neurological decline and ultimately suffered a fatal intracerebral hemorrhage. We demonstrate the importance of the early diagnosis and variable presentation of post-heart-transplant PTLD. The importance of surveillance regardless of EBV status and close monitoring of disease progression due to potential life-threatening complications, such as fatal hemorrhages. Therefore, primary CNS-PTLD remains a challenging disease and is being increasingly recognized with improved transplant recipient survival and prolonged exposure to chronic immunosuppression.

Hemophagocytic Lymphohistiocytosis (HLH) is a rare and serious syndrome characterized by excessive inflammation and tissue damage due to abnormal immune activation. It presents in two main forms: a genetic variant predominantly affecting children, and an acquired form more common in adults, often secondary to infections, malignancies, or autoimmune diseases such as systemic lupus erythematosus (SLE). Macrophage Activation Syndrome (MAS), a subtype of HLH, frequently complicates rheumatologic conditions like systemic juvenile idiopathic arthritis (SJIA) and SLE. It is marked by intense inflammation driven by biomarkers such as interleukin (IL)-18 and IFN-γ. Clinical manifestations of HLH include persistent fever, enlargement of liver and spleen, blood cell deficiencies, elevated ferritin and triglyceride levels, abnormal liver function tests, decreased fibrinogen, and neurological symptoms, posing challenges in differential diagnosis. Diagnostic evaluation typically reveals blood cell deficiencies, elevated triglycerides, decreased fibrinogen, elevated ferritin, impaired natural killer cell function, and increased soluble IL-2 receptor levels. Early recognition and prompt intervention are crucial for improving outcomes in HLH and MAS. Diagnostic criteria incorporate clinical findings and laboratory parameters, supported by scoring systems such as HLH-2004 and HScore. Treatment strategies focus on limiting exposure to harmful agents and targeting specific cytokines like interferon gamma, IL-1, IL-18, and IL-6. Emerging therapies include corticosteroids, cyclosporine, anakinra, and, in severe cases, etoposide, showing promise in managing cytokine-release syndrome post-CAR T cell therapy. Adherence to standardized management protocols and evidence-based guidelines post-stem cell transplantation and CAR T cell therapy is essential for improving patient outcomes, including reduced mortality rates and faster resolution of inflammatory markers. This summary offers a comprehensive overview of HLH and MAS, highlighting diagnostic complexities, therapeutic approaches, and advancements in treatment aimed at enhancing patient care and prognosis.